John Gabriel Connolly, S.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pharmacoepidemiology | 3 | 2024 | 350 | 1.210 |
Why?
|
Lawyers | 1 | 2019 | 38 | 0.630 |
Why?
|
Vasculitis | 1 | 2022 | 522 | 0.600 |
Why?
|
Angioedema | 1 | 2019 | 184 | 0.600 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2020 | 219 | 0.590 |
Why?
|
Parkinson Disease, Secondary | 1 | 2015 | 122 | 0.490 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2019 | 494 | 0.490 |
Why?
|
Thiazolidinediones | 1 | 2015 | 460 | 0.410 |
Why?
|
Propensity Score | 3 | 2020 | 1912 | 0.410 |
Why?
|
Databases, Factual | 5 | 2020 | 7963 | 0.380 |
Why?
|
Epidemiologic Methods | 1 | 2016 | 1335 | 0.370 |
Why?
|
PrPC Proteins | 3 | 2009 | 38 | 0.360 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1661 | 0.350 |
Why?
|
Hypoglycemic Agents | 3 | 2015 | 3085 | 0.300 |
Why?
|
Anticoagulants | 2 | 2022 | 4785 | 0.290 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 3245 | 0.280 |
Why?
|
Medicare | 3 | 2024 | 6774 | 0.250 |
Why?
|
Insurance Claim Review | 2 | 2020 | 741 | 0.240 |
Why?
|
Cohort Studies | 8 | 2022 | 41464 | 0.230 |
Why?
|
Atrial Fibrillation | 1 | 2022 | 5031 | 0.220 |
Why?
|
Hospitalization | 3 | 2022 | 10708 | 0.200 |
Why?
|
Antipsychotic Agents | 1 | 2015 | 3067 | 0.190 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 311 | 0.170 |
Why?
|
Stroke | 1 | 2022 | 9715 | 0.170 |
Why?
|
Data Interpretation, Statistical | 2 | 2020 | 2689 | 0.160 |
Why?
|
Algorithms | 1 | 2020 | 14024 | 0.160 |
Why?
|
PrPSc Proteins | 2 | 2009 | 32 | 0.160 |
Why?
|
Fluoroquinolones | 1 | 2020 | 306 | 0.160 |
Why?
|
Xenopus laevis | 1 | 2002 | 963 | 0.150 |
Why?
|
Isotretinoin | 1 | 2019 | 134 | 0.140 |
Why?
|
Oocytes | 1 | 2002 | 1166 | 0.140 |
Why?
|
Pyridones | 1 | 2022 | 808 | 0.140 |
Why?
|
Diabetes Mellitus | 1 | 2015 | 5838 | 0.130 |
Why?
|
Aortic Aneurysm | 1 | 2020 | 648 | 0.130 |
Why?
|
Odds Ratio | 2 | 2020 | 9644 | 0.130 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2019 | 452 | 0.120 |
Why?
|
Mental Disorders | 1 | 2015 | 6826 | 0.120 |
Why?
|
Alendronate | 1 | 2016 | 175 | 0.120 |
Why?
|
Hyperkinesis | 1 | 2015 | 89 | 0.120 |
Why?
|
Dermatologic Agents | 1 | 2019 | 313 | 0.120 |
Why?
|
Insulin, Long-Acting | 1 | 2014 | 58 | 0.120 |
Why?
|
Computer Simulation | 2 | 2020 | 6233 | 0.120 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 321 | 0.110 |
Why?
|
Affective Disorders, Psychotic | 1 | 2015 | 186 | 0.110 |
Why?
|
Warfarin | 1 | 2022 | 1477 | 0.110 |
Why?
|
Drugs, Generic | 1 | 2019 | 448 | 0.110 |
Why?
|
Simvastatin | 1 | 2016 | 346 | 0.110 |
Why?
|
Cross-Over Studies | 1 | 2019 | 2079 | 0.110 |
Why?
|
Conduct Disorder | 1 | 2015 | 245 | 0.100 |
Why?
|
Drug Utilization | 1 | 2019 | 1186 | 0.100 |
Why?
|
Venous Thrombosis | 1 | 2022 | 1303 | 0.100 |
Why?
|
Risperidone | 1 | 2015 | 381 | 0.100 |
Why?
|
Drug Labeling | 1 | 2014 | 248 | 0.100 |
Why?
|
Osteoporotic Fractures | 1 | 2016 | 410 | 0.090 |
Why?
|
Influenza, Human | 1 | 2022 | 1521 | 0.090 |
Why?
|
United States | 7 | 2024 | 72292 | 0.090 |
Why?
|
Blood Glucose | 3 | 2015 | 6390 | 0.090 |
Why?
|
Monte Carlo Method | 1 | 2016 | 1257 | 0.090 |
Why?
|
Data Collection | 1 | 2019 | 3316 | 0.080 |
Why?
|
Humans | 20 | 2024 | 760740 | 0.080 |
Why?
|
Internationality | 1 | 2014 | 1000 | 0.080 |
Why?
|
Pulmonary Embolism | 1 | 2022 | 2568 | 0.080 |
Why?
|
Benzodiazepines | 1 | 2015 | 1133 | 0.080 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2016 | 1116 | 0.080 |
Why?
|
Bone Density Conservation Agents | 1 | 2016 | 794 | 0.080 |
Why?
|
Insulin | 2 | 2013 | 6593 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2024 | 12143 | 0.070 |
Why?
|
Guideline Adherence | 2 | 2015 | 2218 | 0.070 |
Why?
|
Thiazoles | 1 | 2015 | 1517 | 0.070 |
Why?
|
RNA, Messenger | 1 | 2002 | 12759 | 0.070 |
Why?
|
Electronic Health Records | 1 | 2024 | 4810 | 0.070 |
Why?
|
Prion Diseases | 1 | 2008 | 100 | 0.070 |
Why?
|
Insurance, Health | 1 | 2019 | 2495 | 0.070 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2270 | 0.070 |
Why?
|
Aged | 7 | 2024 | 169092 | 0.060 |
Why?
|
Brain Chemistry | 1 | 2008 | 960 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14649 | 0.060 |
Why?
|
Piperazines | 1 | 2015 | 2521 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2016 | 3567 | 0.060 |
Why?
|
Molecular Weight | 2 | 2005 | 2185 | 0.060 |
Why?
|
Prions | 1 | 2005 | 180 | 0.060 |
Why?
|
Anxiety Disorders | 1 | 2015 | 2724 | 0.050 |
Why?
|
Retrospective Studies | 3 | 2022 | 80583 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7403 | 0.050 |
Why?
|
Depressive Disorder | 1 | 2015 | 3735 | 0.050 |
Why?
|
Platelet Activation | 1 | 2005 | 646 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2019 | 22153 | 0.050 |
Why?
|
Antibodies, Monoclonal | 2 | 2009 | 9171 | 0.050 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2013 | 2746 | 0.050 |
Why?
|
Parkinson Disease | 1 | 2015 | 2878 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2022 | 11458 | 0.050 |
Why?
|
Risk Assessment | 3 | 2022 | 23974 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2015 | 12448 | 0.050 |
Why?
|
Medication Adherence | 1 | 2012 | 2175 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2015 | 7390 | 0.040 |
Why?
|
Female | 9 | 2024 | 392203 | 0.040 |
Why?
|
Male | 8 | 2024 | 360402 | 0.040 |
Why?
|
Psychotic Disorders | 1 | 2015 | 3220 | 0.040 |
Why?
|
Glycosylation | 1 | 2002 | 1098 | 0.040 |
Why?
|
Mass Screening | 1 | 2015 | 5425 | 0.040 |
Why?
|
Cardiovascular Diseases | 2 | 2016 | 15498 | 0.040 |
Why?
|
Cricetinae | 1 | 2002 | 2424 | 0.040 |
Why?
|
Endopeptidases | 1 | 2002 | 774 | 0.040 |
Why?
|
Creutzfeldt-Jakob Syndrome | 2 | 2009 | 93 | 0.040 |
Why?
|
Sertraline | 1 | 2019 | 209 | 0.040 |
Why?
|
Smoking | 1 | 2013 | 9054 | 0.030 |
Why?
|
Protein Transport | 1 | 2002 | 1966 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10754 | 0.030 |
Why?
|
Immunoprecipitation | 2 | 2009 | 876 | 0.030 |
Why?
|
Citalopram | 1 | 2019 | 402 | 0.030 |
Why?
|
Thromboembolism | 1 | 2022 | 991 | 0.030 |
Why?
|
Risk Factors | 2 | 2020 | 74128 | 0.030 |
Why?
|
Models, Animal | 1 | 2002 | 2108 | 0.030 |
Why?
|
Temperature | 1 | 2002 | 2224 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2022 | 58919 | 0.030 |
Why?
|
Prognosis | 1 | 2016 | 29601 | 0.030 |
Why?
|
Blood Platelets | 1 | 2005 | 2478 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2020 | 802 | 0.030 |
Why?
|
Incidence | 2 | 2022 | 21339 | 0.030 |
Why?
|
Legislation, Drug | 1 | 2014 | 214 | 0.030 |
Why?
|
Child, Preschool | 1 | 2015 | 42193 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2002 | 3688 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 3798 | 0.020 |
Why?
|
Risk | 1 | 2022 | 9603 | 0.020 |
Why?
|
Blotting, Western | 2 | 2008 | 5034 | 0.020 |
Why?
|
Pneumonia | 1 | 2020 | 2143 | 0.020 |
Why?
|
Drug Interactions | 1 | 2013 | 1415 | 0.020 |
Why?
|
Gerstmann-Straussler-Scheinker Disease | 1 | 2008 | 10 | 0.020 |
Why?
|
Thrombosis | 1 | 2022 | 2942 | 0.020 |
Why?
|
Epitope Mapping | 1 | 2009 | 297 | 0.020 |
Why?
|
Hybridomas | 1 | 2009 | 442 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2013 | 2925 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2009 | 1057 | 0.020 |
Why?
|
Child | 1 | 2015 | 80089 | 0.020 |
Why?
|
Adolescent | 1 | 2015 | 88247 | 0.020 |
Why?
|
Octoxynol | 1 | 2005 | 77 | 0.020 |
Why?
|
Logistic Models | 1 | 2020 | 13248 | 0.020 |
Why?
|
Ionophores | 1 | 2005 | 107 | 0.020 |
Why?
|
Chromatography, Ion Exchange | 1 | 2005 | 297 | 0.020 |
Why?
|
Chromatography, Affinity | 1 | 2005 | 532 | 0.010 |
Why?
|
Protein Structure, Quaternary | 1 | 2005 | 428 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2002 | 11874 | 0.010 |
Why?
|
Mice | 3 | 2009 | 81368 | 0.010 |
Why?
|
Mice, Knockout | 2 | 2009 | 14388 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 1738 | 0.010 |
Why?
|
Copper | 1 | 2005 | 367 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2012 | 2315 | 0.010 |
Why?
|
Middle Aged | 3 | 2022 | 220603 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2019 | 64572 | 0.010 |
Why?
|
Animals | 3 | 2009 | 168202 | 0.010 |
Why?
|
Primary Health Care | 1 | 2013 | 4677 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 10203 | 0.010 |
Why?
|
Disease Progression | 1 | 2012 | 13495 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2008 | 11069 | 0.010 |
Why?
|
Cell Line | 1 | 2008 | 15577 | 0.010 |
Why?
|
Calcium | 1 | 2005 | 5717 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2012 | 26065 | 0.010 |
Why?
|